I 100% agree "The fact that the company feels confident enough to approach the fda with the 210 data leads me to believe it was sufficient to achieve an endpoint change. "
I also think this may be a blessing in disguise as Bucci is a perfect product for Long Haul Covid19 IMO, and that is based on what is already known.... What if long haulers need a life time drug, like Lupus, MS, RA patients like me do? We know Bucci has been used for RA for 30 years, safely, as a daily pill.
And what if Bucci works as a daily pill for long haul covid19. In other words, Long Haul Covid19 may need a life time time drug, and $RVVTF
So moving the end points is perfect for that. Some data is claiming that a huge % of Covid19 survivors have long Covid. What if the $RVVTF data shows that no one that got the real Bucci has long haul covid19? That may be a stretch actually, but we know enough to connect the dots and predict that Bucci should also be a gang buster daily use drug for long Haul covid19.
Market Data 
Markets 
AI
